On March 5, 2019, Chongqing ZEIN Pharmaceutical Co., Ltd. (short name ZEIN) and South Korea's leading biopharmaceutical company Binex Co., Ltd. held a signing ceremony of strategic alliance in Chongqing. The team led by Senior Partner Wang Haoyu and Partner Li Shuangjiang of ZhongYin (Chongqing) Law Firm will provide legal support for the cross-border cooperation from start to finish, and address and resolve the legal issues involved in the cross-border cooperation, and has assisted ZEIN in entering into this alliance.

BINEX and ZEIN (as the only partner of BINEX on this kind of project in China) will integrate resources in biological medicine, chemical medicine, cell therapy and other fields and will carry out deeper cooperation of mutual trust worldwide. Binex Co., Ltd. is the first and only company in Asia owning a biological medicine with global tracking record, CDMO, which has passed the South Korean GMP certification, European QP audit and more rigorous on-site audits by Merck Serono, MSD, Sanofi and other international pharmaceutical giants. This cooperation is of great significance for promoting the innovative development of the biomedical industry in China and even in Asia.

The team of Wang Haoyu and Li Shuangjiang of ZhongYin (Chongqing) has extensive experience and strong ability in non-litigation practices such as domestic and overseas securities issuance and listing, foreign investment, merger & acquisition and reorganization, private equity investment fund and risk management, and other practice related to finance & securities, corporate affairs and international affairs. It has led or participated in many companies’ A share listing, NEEQ listing, major asset-restructuring, PPP and the like, and served as legal counsel to many listed companies, government departments, state-owned enterprises, private enterprises, and so on. It protects the legitimate interests of clients and provide them with a full range of professional legal services.